Paricalcitol is a vitamin D analog used to treat hyperparathyroidism associated with stage 3 or greater chronic kidney disease. Paricalcitol has been used to reduce parathyroid hormone levels.
- Mechanism
- Curator reviewed
Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring. Preclinical andin vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the VDR, which results in the selective activation of vitamin D responsive pathways. Vitamin D and paricalcitol have been shown to reduce parathyroid hormone levels by inhibiting PTH synthesis and secretion.
- Primary indication
- For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4Curator reviewed · 6 structured indications
- Formula / weight
- C27H44O3 · 416.6365 g/mol (avg)
- First approval
- Canada, 2012 · United States, 1998
- Code names
- COMPOUND-49510
- Brand names
Resolves to
BPKAHTKRCLCHEA-UBFJEZKGSA-NSMILES[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1)[C@H](C)\C=C\[C@H](C)C(C)(C)OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Paricalcitol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account